

PTO/SB/96 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Aventis Pharma S.A.Application No./Patent No. 10/786,810 Filed/Issue Date: February 25, 2004Entitled: Composition of a CB1 Receptor Antagonist and of a Product Which Activates  
Dopaminergic Neurotransmission in the Brain, the Pharmaceutical Compositions  
Comprising Them and Their Use in the Treatment of Parkinson's DiseaseAventis Pharma S.A.

(Name of Assignee)

, a Corporation(Type of Assignee, e.g., corporation, partnership, university, government  
agency, etc.)

States that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by, percentage) of its ownership interest is \_\_\_\_\_ %

In the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel 014764, Frame 0198, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_ Frame \_\_\_\_\_ or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_ Frame \_\_\_\_\_ or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_ Frame \_\_\_\_\_ or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.  
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

June 8, 2005

Date

ROUSSEAU Pierick

Typed or printed name

Signature Executive

Title

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1450

UNITED STATES OF AMERICA

# DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).  
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed  
and for which a patent is sought on the invention entitled:

## COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE

and the specification of which  
(check one)



is attached hereto (Aventis Docket No. ST01023 US CNT)



was filed on February 25, 2004 as U.S. Application Number 10/786,810  
and was amended on (if applicable).



was described and claimed in PCT Int'l Application Number filed on  
and as amended under PCT Article 19 on (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification,  
including the claims as amended by any amendment referred to above.

I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to  
be material to patentability as defined in 37 C.F.R. 1.56.



I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign  
application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at  
least one other country other than the United States of America, listed below and having a filing date before that of  
the application on which priority is claimed. I/We have also identified below any foreign application for patent or  
inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign  
Priority:

0111200  
Number

France  
Country

29/August/2001  
Day/Month/Year Filed

Prior  
Foreign  
Appln(s):

Number

Country

Day/Month/Year Filed



I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional  
application(s) listed below:

Number

Filing Date



I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States  
application(s) or international application designating the United States listed below and, insofar as the subject  
matter of each of the claims of this application is not disclosed in the prior United States application in the manner  
provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose  
information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which  
became available between the filing date of the prior application and the national or PCT international filing date of  
this application.

PCT/FR02/02946  
Application Serial No.

August 28, 2002  
Filing Date

Pending  
Status (Patented, Pending)

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information  
and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements  
and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such  
willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☒ Additional names and signatures are attached.

1. Full name: Jésus BENAVIDES

Signature: Jesus Benavides

Date: 05/09/2005

Country of Citizenship: Spain

Residence: Chatenay Malabry, France  
(City, State/City, and Country only)

P. O. Address: 105 rue Anatole France  
92290 Chatenay Malabry (France)

2. Full name: Daniel BOCCIO

Signature: Daniel Boccio

Date: 05/10/2005

Country of Citizenship: France

Residence: Fayl-Billot, France  
(City, State/City, and Country only)

P. O. Address: 14 rue Georges Darboy  
52500 Fayl-Billot (France)

AUG. 16. 2005 2:22PM

AVENTIS US PAT DEPT

NO. 7542 P. 9/9

3. Full name: Yvette HENIN

Signature: Yvette Henin

Date: May 2<sup>nd</sup> 2005

Country of Citizenship: France

Residence: Paris, France

(City, State/City, and Country only)

P. O. Address: 18, Cours du 7<sup>ème</sup> Art

75019 Paris (France)

4. Full name: Odile PIOT-GROSJEAN

Signature: Odile Piot-Grosjean

Date: May 16<sup>th</sup>, 2005

Country of Citizenship: France

Residence: Choisy Le Roi, France

(City, State/City, and Country only)

P. O. Address: 4 rue Jean-Baptiste Clément

94600 Choisy Le Roi (France)

5. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_

(City and State/City and Country only)

P. O. Address: \_\_\_\_\_

6. Full name: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Country of Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_

(City and State/City and Country only)

P. O. Address: \_\_\_\_\_

Customer No. 005487

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206

P.O. Box 6800

Mail Code D-303A

Bridgewater, NJ 08807-0800

Telephone (908) 231-3364

Telefax (908) 231-2626

Aventis Docket No. ST01023 US CNT